Meloxicam Dosing for a 10-Year-Old Weighing 47 kg
Critical Issue: No BNFC Evidence Available
The provided evidence does not contain any information from the British National Formulary for Children (BNFC) regarding meloxicam dosing in pediatric patients. The available evidence consists primarily of influenza antiviral guidelines and adult meloxicam studies, which are not applicable to your specific question about BNFC pediatric meloxicam dosing.
What the Evidence Shows
Absence of Pediatric Meloxicam Guidelines
- The research evidence available discusses meloxicam use exclusively in adult populations with rheumatoid arthritis and osteoarthritis, with standard adult dosing of 7.5-15 mg daily 1, 2, 3, 4
- No pediatric-specific meloxicam dosing guidelines appear in any of the provided evidence sources
- The guideline evidence provided relates entirely to influenza antiviral medications (amantadine, rimantadine, oseltamivir, zanamivir) and other unrelated medications, not meloxicam 5
Irrelevant Evidence Provided
- The diclofenac dosing guidelines 6, while pediatric-focused, address a different NSAID and cannot be extrapolated to meloxicam dosing
- Other pediatric guidelines for famotidine 7 and dexamethasone 8 are unrelated to the meloxicam question
Clinical Recommendation
You must consult the actual British National Formulary for Children (BNFC) directly, as the evidence provided does not contain BNFC meloxicam dosing information. Without access to BNFC-specific guidance, I cannot provide the requested dosing recommendation based on this evidence set.
Important Caveats
- Meloxicam use in children requires careful consideration of age-appropriate licensing and indications
- Pediatric NSAID dosing must account for both weight and age-specific pharmacokinetic differences
- The BNFC may have specific restrictions on meloxicam use in the 10-year-old age group that are not reflected in adult literature